
Original Article

The Use of Metabolomics to Identify Biological Signatures of Manganese Exposure

Marissa G. Baker^{1,*}, Christopher D. Simpson¹, Yvonne S. Lin²,
Laura M. Shireman² and Noah Seixas¹

¹Department of Environmental and Occupational Health Sciences, University of Washington, 4225 Roosevelt Way NE Suite 100, Seattle, WA 98105, USA; ²Department of Pharmaceutics, University of Washington, H272 Health Science Building, Seattle WA 98195, USA

*Author to whom correspondence should be addressed. Tel: +206-616-4709; e-mail: bakermg@u.washington.edu

Submitted 23 September 2016; revised 6 December 2016; editorial decision 7 December 2016; revised version accepted 21 December 2016.

Abstract

Objectives: Manganese (Mn) is a known neurotoxicant, and given its health effects and ubiquitous nature in metal-working settings, identification of a valid and reproducible biomarker of Mn exposure is of interest. Here, global metabolomics is utilized to determine metabolites that differ between groups defined by Mn exposure status, with the goal being to help inform a potential metabolite biomarker of Mn exposure.

Methods: Mn exposed subjects were recruited from a Mn steel foundry and Mn unexposed subjects were recruited from crane operators at a metal recycling facility. Over the course of a work day, each subject wore a personal inhalable dust sampler (IOM), and provided an end of shift urine sample that underwent global metabolomics profiling. Both exposed and unexposed subjects were divided into a training set and demographically similar validation set. Using a two-sided adjusted *t*-test, relative abundances of all metabolites found were compared between Mn exposed and unexposed training sets, and those with a false discovery rates (FDR) <0.1 were further tested in the validation sets.

Results: Fifteen ions were found to be significantly different (FDR < 0.1) between the exposed and unexposed training sets, and nine of these ions remained significantly different between the exposed and unexposed validation set as well. When further dividing exposure status into 'lower exposure' and 'higher exposure', several of these nine ions exhibited an apparent exposure–response relationship.

Conclusions: This is the first time that metabolomics has been used to distinguish between Mn exposure status in an occupational cohort, though additional work should be done to replicate these findings with a larger cohort. With metabolite identification by name, empirical formula, or pathway, a better understanding of the relationship between Mn exposure and neurotoxic effects could be elucidated, and a potential metabolite biomarker of Mn exposure could be determined.

Keywords: biomarkers of exposure; exposome; exposure assessment; manganese; metabolomics

Introduction

Manganese (Mn) is an established neurotoxicant associated with deleterious cognitive (Mergler et al. 1994; Bouchard et al. 2007; Bowler et al. 2007) and motor (Roels et al. 1985; Roels et al. 1987; Lucchini et al. 1999) health outcomes. Environmental Mn exposures, from traffic or industrial sources, have been shown to increase the prevalence of Parkinsonian disorders (Finkelstein and Jerrett 2007; Lucchini et al. 2007). The American Conference of Governmental Industrial Hygienists (ACGIH) has recommended an 8-hour time weighted average threshold limit value (TWA TLV) of 100 $\mu\text{g}/\text{m}^3$ for inhalable Mn based on neurological endpoints.

While Mn is ubiquitously found in ambient air, drinking water, and foods common to a Western diet, it is in occupational settings where chronic, elevated exposures are most frequently found. Elevated exposures, encountered in either community or occupational settings, make Mn a public health concern in need of further investigation.

Given the negative health effects related to Mn exposure, research has focused on finding both exposure and disease biomarkers for Mn and its related neurological disorders in readily available biofluids such as blood, plasma, and urine, or by using imaging techniques such as magnetic resonance imaging (MRI) or positron emission tomography (PET) scans (Apostoli, Lucchini, and Alessio 2000; Zheng et al. 2011; O'Neal and Zheng 2015; Baker, Criswell, et al. 2015; Baker et al. 2016). However, a lack of understanding of the timing between exposure and uptake (Roth 2006; Baker et al. 2014), natural human variability in Mn (Järvisalo et al. 1992; Baker, Simpson, et al. 2015), and costs or contraindications associated with MRI or PET scans (e.g. metal chips in eyes) make many biomarkers of Mn exposure and effect impractical for use in a field or clinical setting. Thus, the critical barrier to identifying a reliable, reproducible, and easily accessible biomarker of Mn exposure still remains largely unsolved. As such, there is a critical need in the fields of environmental health, neurology, toxicology, and public health to develop informative peripheral biomarkers of Mn exposure and its related diseases, and to better understand the underlying pathophysiology of Mn neurotoxicity.

Global metabolomics is one promising approach to identifying a biomarker of Mn exposure. Metabolomics is the study of the small molecules (<1000 daltons) in biological systems, often important in metabolic function and signaling, or representing a fingerprint of a specific cellular process (Wishart 2010). Global metabolomics is

typically an exploratory analysis method and is a means of hypothesis generation because selection of putative biomarkers in biofluids using this approach is inherently statistical, based on comparisons between thousands of ions. Therefore, the false positives in the analysis represent ions that are statistically significant but are not related to the exposure in question. Results from metabolomics studies tend to have limited utility unless the selected putative ions can be replicated in an independent sample and the chemical nature and biological role of the ions identified (Broadhurst and Kell 2006).

Typically, global metabolomics has been used to identify biomarkers or physiological alterations related to health effects, such as for neurologic diseases (Ibáñez et al. 2012; Hassan-Smith et al. 2012; Sato et al. 2012; Zhang, Sun, and Wang 2013), cancers (Zhang et al. 2012; Wang, Zhang, and Sun 2013), and, of particular relevance to Mn, Parkinson's Disease (Bogdanov et al. 2008; Michell et al. 2008; Ahmed et al. 2009). While using metabolomics to distinguish between patients and controls is more common, using metabolomics to distinguish between exposed and non-exposed persons is a relatively novel concept (especially in occupational settings) and is a key approach in exploring the exposome—the biological signatures of lifelong environmental exposures within individual physiological histories (Wild 2005). Walker et al. (2016) used a metabolome-wide association study (MWAS) framework to investigate metabolic changes in plasma related to trichloroethylene exposure in an occupationally exposed cohort, and were able to link measured exposure to internal dose and measured endogenous metabolites. However, the other few human metabolomics studies investigating biomarkers of exposure have looked only at dietary exposure to vitamins or minerals, not chemical exposures in an environmental or occupational setting (Aistle et al. 2007; Johansson-Persson et al. 2013). Few studies have investigated metabolomics related to Mn exposure, and those that have analyzed biofluids or tissues collected from model organisms, not biofluids collected from humans exposed in an occupational setting (Dorman et al. 2008; Fordahl et al. 2012; Kumar et al. 2015; Neth et al. 2015). Our study of occupationally exposed workers is particularly important given the substantial limitations in available biomarkers of acute and chronic exposure to Mn. The objective of this work is to report on the use of a metabolomics analysis approach to investigate the differences between occupational groups classified by Mn exposure status, which could in turn inform a biomarker of exposure to Mn. Work presented here represents a novel method for exposure assessment in environmental

and occupational health studies and the first time, to our knowledge, that metabolomics has been applied in an occupational setting to distinguish between exposed and unexposed workers.

Methods

During 1 week in October 2014, subjects were recruited from two Puget Sound worksites; Mn exposed subjects ($n = 20$) worked at a Mn foundry and Mn unexposed subjects worked as crane operators in a metal recycling facility ($n = 17$). Data were collected on worker demographics including age, race, and ethnicity. No exclusions were made on the basis of race, ethnicity, or gender, though all enrolled subjects identified as male. For each enrolled subject at both worksites, a personal, full-shift, inhalable dust sample was collected using an Institute of Occupational Medicine (IOM, Edinburgh, UK) sampler, and a single spot urine sample was collected at the end of the same day. The study protocols were approved by the University of Washington Institutional Review Board.

To increase the validity of our findings, both the Mn exposed and unexposed groups were divided into a training set ($n = 12$ in the Mn exposed group, $n = 10$ in the Mn unexposed group) and a demographically similar validation set ($n = 8$ in the exposed group, $n = 7$ in the unexposed group). Urine samples were processed and analyzed without regard to exposure status. After metabolomics data extraction and preprocessing (as described below), statistical analysis of the training data set yielded putative ions related to Mn exposure and a separate analysis was performed to compare the relative abundance of the selected significant ions in the validation data set.

Mn exposure assessment

Personal full-shift inhalable dust sampling was conducted at each location using IOM inhalable dust samplers according to the UK Health and Safety Executive's Methods for the Determination of Hazardous Substances 14/4 (Mark and Vincent 1986; Health and Safety Executive 2014). The collected inhalable dust samples were analyzed at the University of Washington Environmental Health Laboratory for total Mn using inductively coupled plasma mass spectrometry and adjusted for field blanks handled in the same manner as the filters deployed in the field. Measured inhalable Mn concentration were normalized to 8-hour time weighted average concentrations. For the 37 subjects enrolled, three subjects were missing IOM samples (one from the foundry, and two from the scrap metal recycling yard). Missingness was due to pump failure in the field and is believed to be completely at random.

To explore exposure–response relationships, subjects were divided into three categorical exposure levels based on job title and results from inhalable dust sampling: No Exposure (operators at the scrap metal recycling yard, $n = 10$ in the training set and $n = 7$ in the validation set), Lower Exposure (forklift operators, foundry helpers, and molders at the foundry, $n = 7$ in the training set and $n = 3$ in the validation set), and Higher Exposure (melters or pourers at the foundry, $n = 5$ in the training set and $n = 5$ in the validation set).

Urine preparation and metabolomics analysis

After collection in the field, urine samples were immediately stored on dry ice for transport to a -80°C freezer at the University of Washington. All samples were frozen upon arrival to University of Washington and remained frozen in the -80°C freezer until being thawed on wet ice for sample preparation. All urine samples were prepared and analyzed on the same day, approximately 1 month after collection in the field. The procedure is described in full in [Tay-Sontheimer et al. \(2014\)](#). In brief, 200 μl urine was combined with 800 μl acetonitrile containing deuterated internal standards. After protein precipitation, samples were centrifuged and the supernatant was evaporated under nitrogen gas. Samples were reconstituted in methanol:water with 0.4% acetic acid, vortexed, centrifuged, and transferred to glass autosampler vials. A pooled quality control sample was made from 10 randomly selected urine samples and prepared as described above. Samples were analyzed on an Agilent (Santa Clara, CA, USA) 1200 HPLC coupled to Agilent 6520 Accurate Mass quadrupole time-of-flight (Q-TOF) mass spectrometer, calibrated for accurate masses between m/z of 118 to 1700. A 3.5 μm , 2.1 \times 30 mm Agilent Zorbax SB-C8 guard column and a 1.8 μm , 2.1 \times 50 mm Agilent Zorbax SB-Aq analytical column heated to 60°C were used. The mobile phase consisted of 0.2% acetic acid in water (A) and 0.2% acetic acid in methanol (B) with the gradient starting at 2% B and increasing to 98% B in 13 min, held at 98% B for 6 min, followed by re-equilibration to 2% B for 6.5 min at a flow rate of 0.6 ml/min.

Data were acquired over the 25 minute run in both electrospray ionization positive (ESI+) and negative (ESI-) modes to detect cations and anions, respectively.

Data preprocessing

Data from the quality control samples were assessed for signal stability and retention time shifting over the course of the run. Preprocessing of the raw data from the Q-TOF was done using the open-source package *xcms* in

R Studio, developed by the Scripps Center for Metabolomics (Smith et al. 2006; Tautenhahn, Böttcher, and Neumann 2008). We used xcms for feature detection, retention time alignment, and recursive filling of missing peaks. The relative abundance of each ion was normalized by dividing by the sum of the abundances of all ions detected. Signals were multiplied by 10^6 for convenience, were \log_{10} transformed to better approximate Gaussian distributions, and are unitless. Features found in ESI+ and ESI- modes were combined, and further filtered into two data sets: the primary data set and the sensitivity analysis data set. When considering the percent of samples in which an ion was detected, 40 samples (37 subject and 3 pooled quality control samples) were included. The primary data set retained only those ions that were found in at least 50% of all samples ($n = 20$; $P = 1736$ ions), and the sensitivity data set retained those ions that were found in at least 25% of all samples ($n = 10$; $P = 3380$ ions). After filtering, the primary data and sensitivity analysis data sets were each split into a training and a validation data set as described above.

Statistical analyses

Discovery of biomarkers of exposure

The primary data set, split into training and validation data sets, was used for the discovery of biomarkers of exposure. Using the training data, relative abundances of all ions were compared between Mn exposed and unexposed workers using a 2-sided *t*-test. *P* values were adjusted for multiple comparisons using the Benjamini–Hochberg method to control false discovery rates (FDR). Given the exploratory nature of these analyses and the desire to find identify a larger set of potential ions that could distinguish between groups defined by exposure, an FDR <0.1 was considered to be significant. Ions found to be significantly different between the exposed and unexposed workers in the training group were subsequently tested in the validation set. Since the number of statistical comparisons was more limited in the validation set ($n = 15$), the unadjusted *P* values are reported. For those ions in the 50% (primary) data set that were found to be significantly different in the training group and were also significantly different in the validation group, the exposure–response relationship was explored categorically by comparing relative abundances in the three categories of exposure: No Exposure, Lower Exposure, and Higher Exposure.

Sensitivity analysis

The biomarker discovery process was repeated in the sensitivity data set with a 25% filtering step (i.e., less stringent) to see how changing the filtering criteria affected the number of ions found to be different between Mn exposed

and Mn unexposed subjects. For the sensitivity analysis an FDR <0.05 and <0.01 in addition to an FDR <0.1 was considered to be the threshold for significance, to see how changing this criteria affected the number of ions found to be different between Mn exposed and unexposed subjects.

Results


Subject demographics for the Mn exposed and unexposed workers, stratified by training and validation sets, are presented in Table 1. Unexposed workers were slightly older than the exposed workers. The majority of exposed and unexposed workers self-identified as White, though there were more Hispanic workers in the Mn exposed group than the unexposed group. The unexposed workers were nearly equally divided between first and second shift, whereas the exposed workers were predominantly first shift workers. No Mn unexposed workers wore a respirator, but 12 (60%) of the Mn exposed workers self-reported to have worn an N95 dust mask for part or all of the workday. However, the foundry does not have a formal respiratory protection program, and overall respiratory hygiene at the site was observed to be poor. Thus, their use is unlikely to have a substantial effect on their received Mn dose.

Results from personal inhalable dust monitoring are presented as box plots in Figure 1, with the training and validation sets combined, stratified into the three categories of exposure. The mean Mn exposure in the Lower Exposure group ($n = 10$) was $192.0 \mu\text{g}/\text{m}^3$ (standard deviation [SD]: 98.3, range: 98.5 to 374.3) and the mean Mn exposure in the Higher Exposure group ($n = 10$) was $520.7 \mu\text{g}/\text{m}^3$ (SD: 339.0, range: 180.4 to 1243.3). One worker in the No Exposure group had an inhalable dust measurement ($150.8 \mu\text{g}/\text{m}^3$) that was substantially higher than the other workers in the No Exposure group. It is believed this is due to operating a vehicle with windows down near an area where welding was occurring, per worker report. However, this substantially higher exposure could have been due to another exposure source at the scrap yard that was not accounted for. Eighteen of the 34 inhalable Mn samples (53%) exceeded the ACGIH recommended TWA TLV of $100 \mu\text{g}/\text{m}^3$; all of which were collected at the foundry.

Following metabolomics analysis of the urine samples, a total of 1736 ions were found in the primary data set (ions found in at least 50% of the samples). Nineteen ions were found to be significantly different between the Mn exposed and unexposed groups. However, in three instances, it was believed multiple isotopologues or fragments of another significant ion were classified as being significantly different between Mn exposed and

Table 1. Subject demographics by Mn exposure status.

	Mn exposed workers			Mn unexposed workers		
	All (<i>n</i> = 20)	Training (<i>n</i> =12)	Validation (<i>n</i> =8)	All (<i>n</i> =17)	Training (<i>n</i> =10)	Validation (<i>n</i> =7)
	mean ± SD (range)	mean ± SD (range)	mean ± SD (range)	mean ± SD (range)	mean ± SD (range)	mean ± SD (range)
Age	41.9 ± 12.8 (21, 66)	41.8 ± 12.6 (21, 62)	42.1 ± 12.6 (29, 66)	48.1 ± 11.3 (27, 60)	48.3 ± 10.8 (31, 60)	47.7 ± 10.8 (27, 60)
Ethnicity	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
Hispanic	12 (60.0)	7 (58.3)	5 (62.5)	4 (23.5)	3 (30.0)	1 (14.3)
Not Hispanic	8 (40.0)	5 (41.7)	3 (37.5)	13 (76.5)	7 (70.0)	6 (85.7)
Race	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
White	15 (75.0)	9 (75.0)	6 (75.0)	15 (88.2)	9 (90.0)	6 (85.7)
Other	5 (25.0)	3 (25.0)	2 (25.0)	2 (11.8)	1 (10.0)	1 (14.3)
Respirator	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
Yes	12 (60)	7 (58.3)	5 (62.5)	0 (0)	0 (0)	0 (0)
No	8 (40)	5 (41.7)	3 (37.5)	17 (100)	10 (100)	7 (100)
Shift	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)	<i>n</i> (%)
First	17 (85.0)	10 (83.3)	7 (87.5)	9 (52.9)	5 (50.0)	4 (57.1)
Second	3 (15.0)	2 (16.7)	1 (12.5)	8 (47.1)	5 (50.0)	3 (42.7)



For each exposure group, the middle line that divides the box into two parts represents the median value while the top and bottom line of the box represent the 75th and 25th percentiles, respectively. The box represents the interquartile range (IQR) of scores for the group. The whiskers are extended to all values that are no >1.5 × IQR from the edge of the box.

Figure 1. Manganese exposure assessment by Mn exposure group (in µg/m³).

unexposed groups. For these instances, only the ion with the largest relative abundance was retained and reported herein. Thus, a total of 15 unique ions were found to be significantly different between the Mn exposed and unexposed groups (Table 2). Nine of the 15 ions were replicated in the validation set.

The exposure was stratified into three exposure categories (No Exposure, Lower Exposure, and Higher Exposure) to visualize possible exposure-response relationships. The box plots in Figure 2 illustrate the distribution of the abundance of these nine ions in the three exposure groups. Online Supplement 1 details the relative abundance of each of the ions stratified by the three exposure groups. Of the nine ions that replicated in the validation set, the abundance of all but one were increased in the exposed group, and were generally comparable in the training and validation sets. The ion with *m/z* 415.22 and retention time 8.95 minutes was the only ion of the nine to exhibit a lower abundance in the exposed group than in the unexposed group. Many of the ions exhibited an apparent exposure-response relationship across the three categorical exposure groups.

To determine whether the filtering criteria affected the number of ions found to be different between Mn exposed and Mn unexposed subjects, we compared our

original results from the primary data (filtering criteria of ions found in at least 50% of the samples) to the ions identified in the sensitivity data (filtering criteria of ions found in at least 25% of the samples). Table 3 shows the results of the sensitivity analyses when less stringent filtering criteria were used (50% vs. 25% for the primary and sensitivity data sets, respectively) and when considering an FDR threshold of 0.01 and 0.05 as well as 0.1. As 0.1 was chosen *a priori* for the primary analysis, we wished to explore if more stringent FDR would also produce ions of interest. Using the sensitivity data set, the relative abundances of 22 unique ions were found to differ significantly between Mn exposed and unexposed workers in the training set when using a FDR <0.1, and 11 of these ions remained significantly different between the exposed and unexposed workers in the validation set. When considering an FDR threshold of 0.05, 12 ions were found to be different between the exposed and unexposed in the 25% data set and eight were found to be different in the 50% data set. In the 25% data set eight ions remained significant at the 0.05 level in the validation set, while seven remained significant in the 50% data set. Considering an even more stringent FDR of 0.01, eight ions were found to be different between the exposed and unexposed in the 25% data set and four

Table 2. Relative abundance of ions found to be significantly different (FDR < 0.1) between Mn exposed and unexposed subjects in the training group.

m/z	Retention time (mins)	Mode	Mn unexposed (n = 10)			Mn exposed (n = 12)			FDR training ^a	P value validation ^b
			Mean ± SD	CV (%)	% Detected	Mean ± SD	CV (%)	% Detected		
201.02 ^c	3.56	ESI-	2.05 ± 0.51	24.9	70	3.56 ± 0.40	12.4	100	<0.01	<0.01
297.10 ^c	3.98	ESI-	1.78 ± 0.29	16.3	10	3.23 ± 0.42	13.0	92	<0.01	<0.01
553.24	4.03	ESI-	0.76 ± 0.27	35.5	0	1.94 ± 0.58	29.9	75	<0.01	<0.01
160.08	4.21	ESI-	1.49 ± 0.36	24.2	40	2.14 ± 0.34	15.9	92	0.04	0.14
205.07	4.21	ESI-	1.78 ± 0.42	23.6	80	2.46 ± 0.35	14.2	92	0.08	0.13
246.01	4.68	ESI-	0.41 ± 0.76	185.4	0	1.99 ± 0.31	15.6	83	0.01	0.03
311.12	5.18	ESI-	1.45 ± 0.30	20.7	10	2.34 ± 0.34	14.5	92	<0.01	<0.01
415.22	8.95	ESI-	1.58 ± 0.16	10.1	20	2.04 ± 0.30	14.7	75	0.03	0.08
321.10	4.01	ESI+	1.72 ± 0.26	15.1	0	2.47 ± 0.36	14.6	83	0.03	<0.01
229.07	4.20	ESI+	1.59 ± 0.27	17.0	10	2.07 ± 0.26	12.6	67	0.08	0.40
177.11 ^c	4.71	ESI+	1.84 ± 0.37	20.1	30	2.46 ± 0.25	10.2	92	0.08	<0.01
354.23	4.95	ESI+	2.17 ± 0.27	12.4	50	2.62 ± 0.21	8.0	83	0.08	0.20
311.15	6.83	ESI+	2.42 ± 0.22	9.1	80	1.97 ± 0.30	15.2	17	0.10	0.16
403.23	7.72	ESI+	2.04 ± 0.18	8.8	60	1.69 ± 0.19	11.2	17	0.08	0.65
459.22	7.78	ESI+	2.84 ± 0.21	7.4	100	2.41 ± 0.24	10.0	58	0.08	0.08

CV: coefficient of variation; m/z: mass to charge ratio.

^aBenjamini-Hochberg corrected *P* value between Mn unexposed (n = 10) and Mn exposed (n = 12 f) subjects in training group.

^bTwo-sided *t*-test between exposed (n = 8) and unexposed (n = 7) in validation groups.

^cHad known isotopologues or fragments that were also found in the training group with FDR < 0.1.




Figure 2. Box plots of exposure–response relationships for ions identified as different between no Mn exposure, lower Mn exposure, and higher Mn exposure, in both training and validation sets.

were found to be different in the 50% data set. In the 25% data set six ions remained significant at the 0.01 level in the validation set while four remained significant in the 50% data set. One additional ion had a P value of <0.01 in the validation set, but had an FDR >0.01 (but <0.05) in the training set. All ions found to be significant in the primary data set were also found to be significant in the sensitivity data set.

Discussion

We found nine ions to be significantly different in the training and validation sets between groups defined by Mn exposure status (Table 3). An apparent exposure–response relationship emerged for most of the ions when looking at the relative abundances of these nine ions across three exposure groups, though no formal test of trend was done

Table 3. Sensitivity analysis.

	Primary data set (50% filtering)	Sensitivity data set (25% filtering)	Overlapping ions
Total ions	1736	3380	—
FDR < 0.1			
<i>n</i> ions found in training set	15	22	15
<i>n</i> ions found in validation set	9	11	9
FDR < 0.05			
<i>n</i> ions found in training set	8	12	8
<i>n</i> ions found in validation set	7 ^a	8	7 ^a
FDR < 0.01			
<i>n</i> ions found in training set	4	8	4
<i>n</i> ions found in validation set	6 ^b	6	6 ^b

^aIon *m/z* 177.11 RT 4.71 had an FDR <0.05 in the validation set, but had an FDR of 0.08 in the training set.

^bIons *m/z* 177.11 RT 4.71 and *m/z* 321.10 RT 4.01 had FDR<0.01 in the validation set, but had FDRs of 0.08 and 0.03, respectively, in the training set.

for the three groups. Despite the relatively modest number of workers participating in this study, these ions may in fact distinguish between groups defined by Mn exposure status in this occupational cohort and also provides evidence that metabolomics can be used as a method of exposure assessment (or in tandem with traditional exposure assessment techniques) in occupational settings. Exposure assessment using metabolomics methods is a novel and burgeoning field, with many as-yet unexplored applications for highly original and multidisciplinary environmental and occupational health research. The findings presented here represent an essential first step in the development and validation of a biomarker of Mn exposure using global metabolomics techniques.

Notably, work presented here does not include identification (by name or empirical formula) of any of the ions which we found to be significantly different between the Mn exposed and unexposed workers. Analytical work to determine the identities of these seven ions through fragmentation, isolation, and additional mass spectrometry and nuclear magnetic resonance methods is ongoing. However, as detailed by others, identification of unknown ions is a major bottleneck in metabolomics research. Knowing the chemical structure or formula of these promising ions would help to inform the biochemical pathways influenced by Mn exposure and allow us to better elucidate the relationship between exposure and health effect.

A challenge to using metabolomics methods for exposure assessment in occupational cohorts is that any metabolites believed to distinguish between Mn exposure status could be non-specific to Mn exposure. Instead, these metabolites could represent unmeasured confounders that differentiate the two groups, including other workplace

exposures. In human cohorts, it is extremely challenging to comprehensively assess all confounding exposures that would be present in an occupational setting. While many of these workplace exposures (e.g. iron, chromium, nickel) would likely be correlated with Mn exposure, others may be related to specific industrial processes or base metals and not correlated with Mn exposure. It is always a limitation with metabolomics studies that ions found to differentiate between groups could actually relate to unmeasured confounders as opposed to the exposure in question. However, including separate training and validation groups minimizes the identification of false positive signals. We found nine ions to be different between groups defined by exposure in the training data set that were replicated in the validation data set. Additional studies in Mn exposed individuals and appropriate controls should be conducted to verify these results.

Additionally, the workplace is only one of many micro-environments in which these workers spend an appreciable amount of time, and while all such micro-environments have historically been thought of separately (including in this manuscript), it is the interaction of work and non-work factors that together contribute to overall human health (Schulte and Vainio 2010; Schulte et al. 2012). Despite classifying persons into groups defined by exposure or disease for metabolomics studies, at its very nature metabolomics is a reflection of exposures sustained in all micro-environments, and through multiple routes of exposure. While this can make it more challenging to investigate a single exposure, it does make metabolomics a powerful tool for exploring the human exposome, assuming that a life history of exposures can be assessed in a rigorous way.

Despite these inherent limitations and considerations, the novelty of the work presented here should not be minimized. As limits on occupational exposures are becoming increasingly stringent and chronic diseases are being linked to low-level exposures, a new set of exposure assessment tools is necessary to assess how subtle biochemical changes in workers influence their health. Indeed, for an exposure such as Mn, it is likely that the majority of exposure would be sustained in a work environment relative to exposures through dietary or ambient sources, making the workplace a logical setting for investigation of Mn. Research presented here shows that metabolomics is one tool that can be used to find subtle biochemical differences between groups classified by exposure, and would have increased utility in well-characterized prospective longitudinal cohort studies with repeat measures as suggested by Wild, where both work and non-work exposures can be simultaneously assessed, and the contribution of each micro-environment characterized (Wild 2005).

In conclusion, this research presents the first time, to our knowledge, that metabolomics methods have been used in an occupational setting to investigate biochemical differences between Mn exposed and unexposed workers. We hope that, with identification of all or some of these seven promising ions and subsequent interpretation of their biological relevance, a greater understanding of the mechanisms behind manganese's neurotoxic effects. Additionally, we hope that work presented here can be used by others to expand the use of metabolomics-based analyses in occupational exposure assessment. Doing so will inform the use of metabolomics in exposome studies looking to integrate work and non-work factors in interpreting human exposure and health.

Supplementary Data

Supplementary data are available at *Annals of Work Exposures and Health* online.

Acknowledgments

Research reported in this publication was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under the Center for Ecogenetics and Environmental Health, Award Number P30ES007033. Marissa Baker was further supported by a National Institute of Environmental Health Sciences Biostatistics, Epidemiologic, and Bioinformatics Training in Environmental Health, Award Number T32ES015459 and Ruth L. Kirschstein National Research Service Award F31ES027304. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Thanks to Tauri Senn, University of Washington Department of Medicinal Chemistry for help with sample analysis and interpretation.

Conflict of interest

The authors have no conflicts of interest to report.

References

- Ahmed SS, Santosh W, Kumar S, *et al.* (2009) Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. *J Biomed Sci*; **16**: 63.
- Apostoli P, Lucchini R, Alessio L. (2000) Are current biomarkers suitable for the assessment of manganese exposure in individual workers? *Am J Ind Med*; **37**: 283–90.
- Astle J, Ferguson JT, German JB, *et al.* (2007) Characterization of proteomic and metabolomic responses to dietary factors and supplements. *J Nutr*; **137**: 2787–93.
- Baker MG, Criswell SR, Racette BA, *et al.* (2015) Neurological outcomes associated with low-level manganese exposure in an inception cohort of asymptomatic welding trainees. *Scand J Work Environ Health*; **41**: 94–101.
- Baker MG, Simpson CD, Sheppard L, *et al.* (2015) Variance components of short-term biomarkers of manganese exposure in an inception cohort of welding trainees. *J Trace Elem Med Biol*; **29**: 123–9.
- Baker MG, Simpson CD, Stover B, *et al.* (2014) Blood manganese as an exposure biomarker: state of the evidence. *J Occup Environ Hyg*; **11**: 210–7.
- Baker MG, Stover B, Simpson CD, *et al.* (2016) Using exposure windows to explore an elusive biomarker: blood manganese. *Int Arch Occup Environ Health*; **89**: 679–87.
- Bogdanov M, Matson WR, Wang L, *et al.* (2008) Metabolomic profiling to develop blood biomarkers for Parkinson's disease. *Brain*; **131**: 389–96.
- Bouchard M, Mergler D, Baldwin M, *et al.* (2007) Neuropsychiatric symptoms and past manganese exposure in a ferroalloy plant. *Neurotoxicology*; **28**: 290–7.
- Bowler RM, Roels HA, Nakagawa S, *et al.* (2007) Dose-effect relationships between manganese exposure and neurological, neuropsychological and pulmonary function in confined space bridge welders. *Occup Environ Med*; **64**: 167–77.
- Broadhurst DI, Kell DB. (2006) Statistical strategies for avoiding false discoveries in metabolomics and related experiments. *Metabolomics*; **2**: 171–96.
- Dorman DC, Struve MF, Norris A, *et al.* (2008) Metabolomic analyses of body fluids after subchronic manganese inhalation in rhesus monkeys. *Toxicol Sci*; **106**: 46–54.
- Finkelstein MM, Jerrett M. (2007) A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. *Environ Res*; **104**: 420–32.
- Fordahl S, Cooney P, Qiu Y, *et al.* (2012) Waterborne manganese exposure alters plasma, brain, and liver metabolites accompanied by changes in stereotypic behaviors. *Neurotoxicol Teratol*; **34**: 27–36.
- Hassan-Smith G, Wallace GR, Douglas MR, *et al.* (2012) The role of metabolomics in neurological disease. *J Neuroimmunol*; **248**: 48–52.

- Health and Safety Executive. (2014) *MDHS 14/4 General methods for sampling and gravimetric analysis of respirable, thoracic and inhalable aerosols*. UK: Health and Safety Executive.
- Ibáñez C, Simó C, Martín-Álvarez PJ, *et al.* (2012) Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. *Anal Chem*; **84**: 8532–40.
- Järvisalo J, Olkinuora M, Kiilunen M, *et al.* (1992) Urinary and blood manganese in occupationally nonexposed populations and in manual metal arc welders of mild steel. *Int Arch Occup Environ Health*; **63**: 495–501.
- Johansson-Persson A, Barri T, Ulmius M, *et al.* (2013) LC-QTOF/MS metabolomic profiles in human plasma after a 5-week high dietary fiber intake. *Anal Bioanal Chem*; **405**: 4799–809.
- Kumar KK, Goodwin CR, Uhouse MA, *et al.* (2015) Untargeted metabolic profiling identifies interactions between Huntington's disease and neuronal manganese status. *Metallomics*; **7**: 363–70.
- Lucchini R, Apostoli P, Perrone C, *et al.* (1999) Long-term exposure to “low levels” of manganese oxides and neurofunctional changes in ferroalloy workers. *Neurotoxicology*; **20**: 287–97.
- Lucchini RG, Albini E, Benedetti L, *et al.* (2007) High prevalence of Parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries. *Am J Ind Med*; **50**: 788–800.
- Mark D, Vincent JH. (1986) A new personal sampler for airborne total dust in workplaces. *Ann Occup Hyg*; **30**: 89–102.
- Mergler D, Huel G, Bowler R, *et al.* (1994) Nervous system dysfunction among workers with long-term exposure to manganese. *Environ Res*; **64**: 151–80.
- Michell AW, Mosedale D, Grainger DJ, *et al.* (2008) Metabolomic analysis of urine and serum in Parkinson's disease. *Metabolomics*; **4**: 191–201.
- Neth K, Lucio M, Walker A, *et al.* (2015) Changes in brain metallome/metabolome pattern due to a single i.v. injection of manganese in rats. *PLOS ONE*; **10**: e0138270.
- O'Neal SL, Zheng W. (2015) Manganese toxicity upon overexposure: a decade in review. *Curr Environ Health Rep*; **2**: 315–28.
- Roels H, Lauwerys R, Buchet JP, *et al.* (1987) Epidemiological survey among workers exposed to manganese: effects on lung, central nervous system, and some biological indices. *Am J Ind Med*; **11**: 307–27.
- Roels H, Sarhan MJ, Hanotiau I, *et al.* (1985) Preclinical toxic effects of manganese in workers from a Mn salts and oxides producing plant. *Sci Total Environ*; **42**: 201–6.
- Roth JA. (2006) Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination. *Biol Res*; **39**: 45–57.
- Sato Y, Suzuki I, Nakamura T, *et al.* (2012) Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. *J Lipid Res*; **53**: 567–76.
- Schulte P, Vainio H. (2010) Well-being at work—overview and perspective. *Scand J Work Environ Health*; **36**: 422–9.
- Schulte PA, Pandalai S, Wulsin V, *et al.* (2012) Interaction of occupational and personal risk factors in workforce health and safety. *Am J Public Health*; **102**: 434–48.
- Smith CA, Want EJ, O'Maille G, *et al.* (2006) XCMS: processing mass spectrometry data for metabolite profiling using non-linear peak alignment, matching, and identification. *Anal Chem*; **78**: 779–87.
- Tautenhahn R, Böttcher C, Neumann S. (2008) Highly sensitive feature detection for high resolution LC/MS. *BMC Bioinformatics*; **9**: 504.
- Tay-Sontheimer J, Shireman LM, Beyer RP, *et al.* (2014) Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. *Pharmacogenomics*; **15**: 1947–62.
- Walker DI, Uppal K, Zhang L, *et al.* (2016) High-resolution metabolomics of occupational exposure to trichloroethylene. *Int J Epidemiol*; **45**: 1517–27.
- Wang XJ, Zhang AH, Sun H. (2013) Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. *Hepatology*; **57**: 2072–77.
- Wild CP. (2005) Complementing the genome with an “exposome”: the outstanding challenge of environmental exposure measurement in molecular epidemiology. *Cancer Epidemiol Biomarkers Prev*; **14**: 1847–50.
- Wishart DS. (2010) *Computational approaches to metabolomics*. New York, NY: Bioinformatics Methods in Clinical Research, Springer.
- Zhang AH, Sun H, Wang XJ. (2013) Recent advances in metabolomics in neurological disease, and future perspectives. *Anal Bioanal Chem*; **405**: 8143–50.
- Zhang J, Bowers J, Liu L, *et al.* (2012) Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. *PLOS ONE*; **7**: e30181.
- Zheng W, Fu SX, Dydak U, *et al.* (2011) Biomarkers of manganese intoxication. *Neurotoxicology*; **32**: 1–8.